Roche's Ventana Medical Systems will develop a companion diagnostic test with Germany's Merck KGaA that can be used for many different cancer types.
Roche is lending its diagnostic technology to Ferring Pharmaceuticals to develop a personalized treatment for female infertility.
Definiens secured financing to grow its existing imaging-analysis business and to expand into tissue diagnostics. New investor Wellington Partners led the €15 million ($20.4 million) financing and joined the board.
Seattle's NanoString Technologies stands to make up to $45 million if it can come up with a successful companion diagnostic test to screen for a subset of lymphoma patients who will benefit from Celgene's blockbuster drug Revlimid.
Almac Group saved some stellar news for the 2014 ASCO Annual Meeting in Chicago. The U.K. life sciences contract manufacturer said it validated a new diagnostic test that spots a subset of ovarian cancer patients with greater survival odds following standard chemotherapy who should avoid a specific Roche drug.
Qiagen and Eli Lilly have joined forces for their fourth companion diagnostics project, building on the momentum of past collaborations to develop assay panels for cancer.
Qiagen and Eli Lilly have clicked well enough in previous companion diagnostics development projects that they're signing up for a fourth go-around.
Qiagen gained FDA approval for a companion diagnostic test that will help spot patients with metastatic colorectal cancer who might benefit most from Amgen's drug Vectibix. The regulatory milestone represents another advance in the Dutch company's growing focus on personalized medicine.
Abbott Laboratories will develop a companion diagnostic test for a lymphoma/autoimmune drug now in clinical testing at Idera Pharmaceuticals.
Qiagen reported adjusted net income of $53.7 million on sales of $317.4 million in the first quarter. Net sales rose 4.5% year-over-year, and net income was up 11.6% at constant exchange rates.